8-K: Corcept Therapeutics: DOJ Declines Intervention in Lawsuit

Corcept Therapeutics announced the U.S. Department of Justice will not intervene in a civil lawsuit filed by a former employee.

Summary

• Corcept Therapeutics learned on May 19, 2026, that the U.S. Department of Justice (DOJ) has elected not to intervene in a civil qui tam action filed against the company.
• This lawsuit, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., was initiated in February 2017 by a former employee.
• The DOJ, along with the California Department of Insurance and named Plaintiff States, have all declined to intervene.
• The company had previously responded to a records subpoena from the DOJ in November 2021 concerning the sale and promotion of Korlym.
• An amended complaint was served on the company on June 2, 2026.
• Corcept Therapeutics intends to vigorously defend against all claims made by the relator.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the DOJ's decision to not intervene reduces the immediate threat of government prosecution, although the underlying lawsuit persists.

Positives

• The Department of Justice, California Department of Insurance, and named Plaintiff States have declined to intervene in the civil lawsuit, indicating a reduced risk of government involvement.
• The company has stated its intention to vigorously defend against the claims, suggesting confidence in its position.

Negatives

• A civil qui tam action initiated by a former employee remains active, with an amended complaint filed on June 2, 2026.
• The company faces ongoing legal defense costs and potential reputational impact from the lawsuit.

Risks

• The company must continue to defend against the relator's claims, which could result in significant legal expenses and potential adverse judgments.
• The lawsuit involves allegations related to the sale and promotion of Korlym, and the company's relationships with healthcare professionals.

Future Outlook

The company intends to vigorously defend against all of the relator's claims. Forward-looking statements are subject to risks and uncertainties detailed in periodic SEC filings.

Management Comments

• The Company intends to vigorously defend against all of the Relators claims.

Industry Context

StockSavvy.ai notes that pharmaceutical companies often face litigation related to drug promotion and sales practices. The DOJ's decision not to intervene in this qui tam action may suggest a lower perceived risk or merit by the government, though the relator can still pursue the case.

Legal Proceedings

• Civil qui tam action: U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc., No. 17-CV-1303 (SRC) (D.N.J.).
• The DOJ, California Department of Insurance, and named Plaintiff States have declined to intervene.
• The company is defending against claims related to the sale and promotion of Korlym and its relationships with healthcare professionals.

Stakeholder Impact

• Shareholders: Potential for continued legal costs and uncertainty, but reduced risk of significant government penalties.
• Employees: Continued focus on defending the company's practices.
• Customers: No direct impact on access to Korlym is indicated.

Next Steps

• Corcept Therapeutics will continue to defend against the relator's claims in the civil action.
• The company will continue to monitor and respond to legal developments in the case.

Key Dates

Recommendation

The DOJ's decision not to intervene is a positive sign, reducing the immediate risk profile. However, the ongoing civil lawsuit initiated by a former employee, with an amended complaint filed, still presents legal and financial uncertainties. A 'hold' recommendation reflects the balance between reduced government risk and the persistence of private litigation.

Keywords

Corcept Therapeutics, 8-K Filing, DOJ, Qui Tam Lawsuit, Korlym, Legal Proceedings, Healthcare Promotion, Securities Filing